SparingVision SA, a developer of gene therapies for retinal diseases, has appointed Anjeza Gjino as chief financial officer. She had been interim CFO since July 2024. With experience in scaling-up and financing biotech companies, Ms Gjino will support SparingVision as a growing, clinical company with one gene therapy programme in a Phase 2 trial and a second soon entering Phase 1. Previously, Ms Gjino was CFO at Cyclerion Therapeutics, where she played a role in the company’s launch and public listing on Nasdaq in 2019.
SparingVision announced the appointment on 3 March 2025.
Copyright 2025 Evernow Publishing Ltd.